See more : GigaCloud Technology Inc. (GCT) Income Statement Analysis – Financial Results
Complete financial analysis of Inotiv, Inc. (NOTV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inotiv, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Avantium N.V. (0RNP.L) Income Statement Analysis – Financial Results
- Lloyds Engineering Works Limited (LLOYDSENGG.NS) Income Statement Analysis – Financial Results
- Jahwa Electronics. Co., Ltd (033240.KS) Income Statement Analysis – Financial Results
- Verastem, Inc. (0LOV.L) Income Statement Analysis – Financial Results
- Standard Uranium Ltd. (STTDF) Income Statement Analysis – Financial Results
Inotiv, Inc. (NOTV)
About Inotiv, Inc.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 490.74M | 572.43M | 547.66M | 89.61M | 60.47M | 43.62M | 26.35M | 24.24M | 20.44M | 22.70M | 24.58M | 22.07M | 28.21M | 33.14M | 28.78M | 31.78M | 41.70M | 45.25M | 43.05M | 42.40M | 37.15M | 29.84M | 26.51M | 25.27M | 19.22M | 19.90M | 18.20M | 14.90M |
| Cost of Revenue | 379.57M | 406.98M | 390.44M | 59.45M | 42.23M | 30.70M | 18.23M | 16.55M | 16.02M | 15.21M | 16.62M | 15.01M | 21.37M | 22.64M | 21.45M | 24.18M | 26.36M | 31.45M | 29.24M | 27.05M | 25.62M | 19.43M | 15.95M | 13.15M | 10.58M | 9.20M | 7.60M | 5.80M |
| Gross Profit | 111.17M | 165.44M | 157.21M | 30.16M | 18.24M | 12.92M | 8.12M | 7.70M | 4.43M | 7.49M | 7.96M | 7.06M | 6.84M | 10.51M | 7.33M | 7.60M | 15.33M | 13.79M | 13.81M | 15.34M | 11.53M | 10.41M | 10.56M | 12.12M | 8.64M | 10.70M | 10.60M | 9.10M |
| Gross Profit Ratio | 22.65% | 28.90% | 28.71% | 33.65% | 30.16% | 29.62% | 30.81% | 31.75% | 21.65% | 32.99% | 32.39% | 31.97% | 24.24% | 31.70% | 25.48% | 23.92% | 36.77% | 30.48% | 32.08% | 36.19% | 31.05% | 34.89% | 39.84% | 47.95% | 44.95% | 53.77% | 58.24% | 61.07% |
| Research & Development | 0.00 | 0.00 | 0.00 | 405.00K | 950.00K | 627.00K | 596.00K | 465.00K | 496.00K | 715.00K | 658.00K | 454.00K | 542.00K | 534.00K | 546.00K | 762.00K | 781.00K | 881.00K | 1.44M | 1.33M | 1.10M | 1.33M | 1.52M | 1.61M | 1.81M | 2.00M | 2.20M | 1.60M |
| General & Administrative | 77.03M | 108.23M | 82.44M | 30.38M | 16.98M | 9.53M | 5.97M | 4.90M | 4.58M | 5.07M | 4.94M | 4.41M | 5.52M | 5.56M | 6.12M | 7.67M | 11.73M | 10.43M | 14.73M | 12.78M | 10.18M | 8.28M | 7.42M | 7.02M | 6.39M | 6.50M | 6.80M | 5.90M |
| Selling & Marketing | 20.88M | 19.09M | 16.65M | 3.52M | 3.37M | 2.91M | 1.54M | 1.05M | 1.42M | 1.40M | 1.66M | 1.37M | 3.26M | 3.12M | 2.67M | 3.30M | 3.91M | 2.78M | 0.00 | 0.00 | 0.00 | 2.85B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 97.92M | 127.32M | 99.09M | 33.89M | 20.35M | 12.45M | 7.51M | 5.95M | 6.00M | 6.47M | 6.60M | 5.77M | 8.79M | 8.69M | 8.78M | 10.97M | 11.73M | 10.43M | 14.73M | 12.78M | 10.18M | 8.28M | 7.42M | 7.02M | 6.39M | 6.50M | 6.80M | 5.90M |
| Other Expenses | 99.66M | 119.59M | 85.57M | 1.48M | 15.00K | 9.00K | 6.00K | 5.00K | 6.00K | 5.00K | 9.00K | 7.00K | 12.00K | 0.00 | 0.00 | 472.00K | 24.00K | 92.00K | 1.06M | -21.43K | 0.00 | 0.00 | 0.00 | 0.00 | 1.64M | 1.30M | 900.00K | 500.00K |
| Operating Expenses | 197.58M | 246.90M | 184.66M | 35.77M | 21.30M | 13.07M | 8.10M | 6.42M | 6.49M | 7.19M | 7.25M | 6.23M | 9.33M | 9.22M | 9.33M | 11.73M | 12.54M | 11.40M | 17.23M | 14.08M | 11.28M | 9.61M | 8.94M | 8.63M | 9.83M | 9.80M | 9.90M | 8.00M |
| Cost & Expenses | 577.15M | 653.89M | 575.10M | 95.22M | 63.53M | 43.77M | 26.33M | 22.96M | 22.51M | 22.39M | 23.88M | 21.24M | 30.70M | 31.86M | 30.78M | 35.91M | 38.90M | 42.86M | 46.47M | 41.14M | 36.90M | 29.04M | 24.89M | 21.78M | 20.42M | 19.00M | 17.50M | 13.80M |
| Interest Income | 0.00 | 0.00 | 29.70M | 1.68M | 1.49M | 642.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 46.88M | 43.02M | 29.70M | 1.68M | 1.49M | 642.00K | 274.00K | 375.00K | 399.00K | 287.00K | 488.00K | 649.00K | 714.00K | 706.00K | 1.03M | 1.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 57.12M | 54.72M | 49.32M | 7.56M | 4.98M | 2.72M | 1.86M | 1.68M | 1.56M | 1.41M | 1.60M | 1.72M | 2.28M | 2.13M | 2.32M | 2.65M | 3.01M | 3.46M | 3.89M | 3.44M | 3.44M | 2.68M | 2.04M | 1.76M | 1.64M | 1.30M | 900.00K | 500.00K |
| EBITDA | -26.76M | -26.51M | -273.42M | 15.37M | 1.03M | 2.57M | 1.88M | 2.96M | -1.29M | 1.71M | 1.02M | 2.55M | -3.40M | 3.43M | 327.00K | -1.95M | 5.81M | 2.39M | 366.00K | 4.72M | 3.67M | 3.48M | 3.67M | 5.25M | 444.11K | 2.20M | 1.60M | 1.60M |
| EBITDA Ratio | -5.45% | -4.63% | -6.83% | 8.71% | -5.04% | -0.33% | 0.08% | 5.29% | -10.09% | 1.36% | 9.41% | 3.79% | -8.79% | 10.32% | 1.13% | -4.66% | 13.97% | 13.12% | 3.53% | 11.04% | 9.75% | 10.07% | 13.38% | 20.67% | 2.74% | 10.55% | 8.24% | 10.74% |
| Operating Income | -86.41M | -81.46M | -27.45M | 1.53M | -3.06M | -153.00K | 14.00K | 1.28M | -3.04M | 909.00K | 334.00K | 830.00K | -5.69M | 1.29M | -2.00M | -4.60M | 2.79M | 2.39M | -3.42M | 1.26M | 254.00K | 800.00K | 1.63M | 3.49M | -1.19M | 900.00K | 700.00K | 1.10M |
| Operating Income Ratio | -17.61% | -14.23% | -5.01% | 1.71% | -5.07% | -0.35% | 0.05% | 5.27% | -14.87% | 4.00% | 1.36% | 3.76% | -20.16% | 3.88% | -6.94% | -14.47% | 6.70% | 5.28% | -7.95% | 2.97% | 0.68% | 2.68% | 6.14% | 13.81% | -6.20% | 4.52% | 3.85% | 7.38% |
| Total Other Income/Expenses | -44.35M | -42.78M | -89.00M | 501.00K | -1.48M | -633.00K | -268.00K | -370.00K | -204.00K | 205.00K | -1.40M | -41.00K | -702.00K | -694.00K | -1.03M | -1.06M | -971.00K | -891.00K | -2.67M | -933.00K | -832.29K | -229.00K | -79.29K | -383.49K | -621.01K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -130.76M | -124.24M | -352.45M | 6.12M | -4.54M | -786.00K | -254.00K | 908.00K | -3.24M | 1.11M | -1.06M | 789.00K | -6.39M | 593.00K | -3.02M | -5.66M | 1.82M | 1.50M | -4.44M | 291.39K | -607.00K | 570.58K | 1.55M | 3.11M | -1.81M | 900.00K | 700.00K | 1.10M |
| Income Before Tax Ratio | -26.65% | -21.70% | -64.36% | 6.83% | -7.50% | -1.80% | -0.96% | 3.75% | -15.87% | 4.91% | -4.32% | 3.58% | -22.65% | 1.79% | -10.51% | -17.81% | 4.37% | 3.31% | -10.30% | 0.69% | -1.63% | 1.91% | 5.84% | 12.29% | -9.43% | 4.52% | 3.85% | 7.38% |
| Income Tax Expense | -21.88M | -19.34M | -15.19M | -4.78M | 147.00K | 4.00K | -60.00K | 24.00K | -14.00K | 25.00K | 7.00K | 16.00K | 2.00K | 50.00K | -333.00K | -197.00K | 1.33M | 573.00K | -1.83M | 392.39K | -403.00K | 483.27K | 480.99K | 1.34M | -431.30K | 300.00K | 300.00K | 400.00K |
| Net Income | -108.45M | -105.14M | -337.26M | 10.90M | -4.69M | -790.00K | -194.00K | 884.00K | -3.23M | 1.09M | -1.07M | 773.00K | -6.39M | 543.00K | -2.69M | -5.46M | -1.49M | 926.00K | -2.61M | -101.00K | -203.00K | 87.31K | 1.07M | 1.77M | -1.38M | 600.00K | 400.00K | 700.00K |
| Net Income Ratio | -22.10% | -18.37% | -61.58% | 12.16% | -7.75% | -1.81% | -0.74% | 3.65% | -15.80% | 4.80% | -4.35% | 3.50% | -22.65% | 1.64% | -9.35% | -17.19% | -3.57% | 2.05% | -6.06% | -0.24% | -0.55% | 0.29% | 4.02% | 6.99% | -7.19% | 3.02% | 2.20% | 4.70% |
| EPS | -5.89 | -4.10 | -13.85 | 0.83 | -0.43 | -0.08 | -0.02 | 0.11 | -0.40 | 0.14 | -0.13 | 0.10 | -0.89 | -0.74 | -0.55 | -1.11 | -0.30 | 0.19 | -0.53 | -0.02 | -0.04 | 0.01 | 0.23 | 0.39 | -0.30 | 0.13 | 0.10 | 0.30 |
| EPS Diluted | -5.89 | -4.10 | -13.85 | 0.79 | -0.43 | -0.08 | -0.02 | 0.10 | -0.40 | 0.07 | -0.13 | 0.09 | -0.89 | -0.74 | -0.55 | -1.11 | -0.30 | 0.19 | -0.53 | -0.02 | -0.04 | 0.01 | 0.23 | 0.38 | -0.30 | 0.12 | 0.09 | 0.21 |
| Weighted Avg Shares Out | 25.90M | 25.64M | 24.35M | 13.19M | 10.85M | 10.38M | 8.77M | 8.18M | 8.11M | 8.08M | 7.96M | 7.66M | 7.16M | 5.67M | 4.92M | 4.92M | 4.91M | 4.91M | 4.88M | 4.87M | 4.86M | 4.66M | 4.58M | 4.56M | 4.55M | 4.51M | 4.12M | 4.39M |
| Weighted Avg Shares Out (Dil) | 25.90M | 25.64M | 24.35M | 13.87M | 10.85M | 10.38M | 8.77M | 8.73M | 8.11M | 8.79M | 7.96M | 8.37M | 7.16M | 5.67M | 4.92M | 4.92M | 4.97M | 4.96M | 4.88M | 4.87M | 4.86M | 4.67M | 4.63M | 4.60M | 4.55M | 4.68M | 4.40M | 4.39M |
Inotiv, Inc. to Present at Jefferies 2023 Healthcare Conference
Inotiv, Inc. to Participate in May Investor Conferences
Wall Street Analysts Predict a 168.98% Upside in Inotiv, Inc. (NOTV): Here's What You Should Know
Inotiv, Inc. (NOTV) Q2 2023 Earnings Call Transcript
Inotiv, Inc. Expands Safety Pharmacology Offering to Include Cardiopulmonary Telemetry
Inotiv, Inc. to Report Fiscal 2023 Second Quarter Financial Results and Host Conference Call on Thursday, May 11, 2023
Inotiv, Inc. (NOTV) Q1 2023 Earnings Call Transcript
Inotiv, Inc. Announces First Quarter Fiscal 2023 Financial Results
Inotiv, Inc. to Report Fiscal 2023 First Quarter Financial Results and Host Conference Call on Monday, February 13, 2023
INOTIV INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Inotiv, Inc. - NOTV
Source: https://incomestatements.info
Category: Stock Reports